Skip to the main content

Professional paper

https://doi.org/10.15836/ccar.2015.28

Evidence-based therapy with Krka’s statins in patients in primary and secondary prevention of cardiovascular disease.

Urben Brumen ; Krka, d. d., Novo mesto, Slovenia
Mateja Grošelj ; Krka, d. d., Novo mesto, Slovenia
Breda Barbič-Žagar orcid id orcid.org/0000-0002-1173-7361 ; Krka, d. d., Novo mesto, Slovenia


Full text: croatian pdf 581 Kb

versions

page 98-105

downloads: 382

cite

Full text: english pdf 581 Kb

versions

page 98-105

downloads: 695

cite


Abstract

Statins have been proven to reduce cardiovascular morbidity and mortality in primary and secondary prevention of cardiovascular disease. However, statin treatment is still not optimal, with the majority of patients not achieving the maximum benefits of this preventive strategy. Krka offers a wide range of statins that have been extensively studied. The studies have provided clear and conclusive evidence about the benefits of atorvastatin (Atoris®) and rosuvastatin (Roswera®) in primary and secondary prevention patients, including effective management of the total lipid profile, achievement of target lipid levels, prevention of severe ischemic outcomes in patients with acute coronary syndrome, protective pleiotropic effects and a good safety profile. Clinical studies with Krka’s statins represent an important contribution to a better management of hyperlipidemia in different groups of patients

Keywords

statins; primary prevention; secondary prevention; clinical studies; efficacy; safety

Hrčak ID:

139862

URI

https://hrcak.srce.hr/139862

Publication date:

18.5.2015.

Article data in other languages: croatian

Visits: 1.754 *